OCGN

Ocugen (OCGN)

About Ocugen (OCGN)

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

Details

Daily high
$1.01
Daily low
$0.94
Price at open
$0.96
52 Week High
$2.10
52 Week Low
$0.34
Market cap
283.5M
Dividend yield
0.00%
Volume
2.2M
Avg. volume
3.6M
P/E ratio
-5.34

Ocugen News

Details

Daily high
$1.01
Daily low
$0.94
Price at open
$0.96
52 Week High
$2.10
52 Week Low
$0.34
Market cap
283.5M
Dividend yield
0.00%
Volume
2.2M
Avg. volume
3.6M
P/E ratio
-5.34